Transgene Presents Data From Phase I Clinical Trial Confirming the Potential of the Oncolytic Virus TG6002
Press release content from Business Wire. The AP news staff was not involved in its creation.
Source: apnews.com
📰 Philippe Erbs News
Philippe Erbs News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Philippe Erbs. Real-time updates on events, politics, business and more.
Transgene Presents Initial Phase I Data of TG6002, Highlighting the Potential of the Intravenous Administration of Its Oncolytic Viruses
Press release content from Business Wire. The AP news staff was not involved in its creation. Transgene Presents Initial Phase I Data of TG6002, Highlighting the Potential of the Intravenous Administration of Its Oncolytic Viruses April 9, 2021 GMT Regulatory News: Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces initial promising results from a Phase I study combining intravenous (IV) oncolyt...
Source: apnews.com